Surgalign (SRGA) Stock Price, News & Analysis

Company Overview

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. It offers products for thoracolumbar procedures, including Streamline TL spinal fixation system, a system for degenerative and complex spine procedures; and Streamline MIS spinal fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops augmented reality and artificial intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois. On June 19, 2023, Surgalign Holdings, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.18 to $1.22
• 52-Week Range: N/A
• Volume: 8.72 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $1.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SRGA Stock Analysis - Frequently Asked Questions

How were Surgalign's earnings last quarter?

Surgalign Holdings, Inc. (NASDAQ:SRGA) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($3.60) earnings per share for the quarter, missing the consensus estimate of ($2.70) by $0.90. The firm earned $20.55 million during the quarter, compared to analysts' expectations of $22.55 million. Surgalign had a negative net margin of 64.63% and a negative trailing twelve-month return on equity of 983.11%.

When did Surgalign's stock split?

Surgalign's stock reverse split on Tuesday, May 17th 2022. The 1-30 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Surgalign own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surgalign investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Ashford Hospitality Trust (AHT), NVIDIA (NVDA), NIO (NIO) and

Company Calendar

• Last Earnings: 11/09/2021
• Today: 1/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SRGA
• CUSIP: N/A
• CIK: 1760173
• Web: www.surgalign.com
• Phone: (224) 303-4651
• Fax: 386-418-0342
• Employees: 217
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($8.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-54,600,000.00
• Net Margins: -64.63%
• Pretax Margin: -66.00%
• Return on Equity: -983.11%
• Return on Assets: -74.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.67
• Quick Ratio: 2.00

Sales & Book Value

• Annual Sales: $81.98 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.81) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 9,240,000
• Free Float: 8,964,000
• Market Cap: $1.69 million
• Optionable: Optionable
• Beta: 1.55